Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancer.
West EJ, Sadoun A, Bendjama K, Erbs P, Smolenschi C, Cassier PA, de Baere T, Sainte-Croix S, Brandely M, Melcher AA, Ismail F, Scott KJ, Bennett A, Banks E, Gasior E, Kent S, Kurzawa M, Hammond C, Patel JV, Collinson FJ, Twelves C, Anthoney DA, Swinson D, Samson A. West EJ, et al. Among authors: melcher aa. Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-2498. Online ahead of print. Clin Cancer Res. 2025. PMID: 39785814
Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment.
Jennings VA, Rumbold-Hall R, Migneco G, Barr T, Reilly K, Ingram N, St Hilare I, Heaton S, Alzamel N, Jackson D, Ralph C, Banerjee S, McNeish I, Bell JC, Melcher AA, Ilkow C, Cook GP, Errington-Mais F. Jennings VA, et al. Among authors: melcher aa. Front Immunol. 2024 Dec 23;15:1500570. doi: 10.3389/fimmu.2024.1500570. eCollection 2024. Front Immunol. 2024. PMID: 39763667 Free PMC article.
CXCL12-targeted immunomodulatory gene therapy reduces radiation-induced fibrosis in healthy tissues.
Paget JT, Ward JA, McKean AR, Mansfield DC, McLaughlin M, Kyula-Currie JN, Smith HG, Roulstone V, Li C, Zhou Y, Hardiman T, Grigoriadis A, O'Brien Coon D, Irshad S, Melcher AA, Harrington KJ, Khan A. Paget JT, et al. Among authors: melcher aa. Mol Cancer Ther. 2024 Dec 12. doi: 10.1158/1535-7163.MCT-23-0872. Online ahead of print. Mol Cancer Ther. 2024. PMID: 39666014
Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy.
Patin EC, Nenclares P, Chan Wah Hak C, Dillon MT, Patrikeev A, McLaughlin M, Grove L, Foo S, Soliman H, Barata JP, Marsden J, Baldock H, Gkantalis J, Roulstone V, Kyula J, Burley A, Hubbard L, Pedersen M, Smith SA, Clancy-Thompson E, Melcher AA, Ono M, Rullan A, Harrington KJ. Patin EC, et al. Among authors: melcher aa. Nat Commun. 2024 Aug 13;15(1):6923. doi: 10.1038/s41467-024-51236-6. Nat Commun. 2024. PMID: 39134540 Free PMC article.
OX40 and 4-1BB delineate distinct immune profiles in sarcoma.
Melake MJ, Smith HG, Mansfield D, Davies E, Dillon MT, Wilkins AC, Patin EC, Pedersen M, Buus R, Melcher AA, Thway K, Miah AB, Zaidi SH, Hayes AJ, Fenton TR, Harrington KJ, McLaughlin M. Melake MJ, et al. Among authors: melcher aa. Oncoimmunology. 2022 May 9;11(1):2066050. doi: 10.1080/2162402X.2022.2066050. eCollection 2022. Oncoimmunology. 2022. PMID: 35558159 Free PMC article.
Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients.
Samson A, West EJ, Carmichael J, Scott KJ, Turnbull S, Kuszlewicz B, Dave RV, Peckham-Cooper A, Tidswell E, Kingston J, Johnpulle M, da Silva B, Jennings VA, Bendjama K, Stojkowitz N, Lusky M, Prasad KR, Toogood GJ, Auer R, Bell J, Twelves CJ, Harrington KJ, Vile RG, Pandha H, Errington-Mais F, Ralph C, Newton DJ, Anthoney A, Melcher AA, Collinson F. Samson A, et al. Among authors: melcher aa. Cancer Immunol Res. 2022 Jun 3;10(6):745-756. doi: 10.1158/2326-6066.CIR-21-0171. Cancer Immunol Res. 2022. PMID: 35439304 Free PMC article.
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.
Patin EC, Dillon MT, Nenclares P, Grove L, Soliman H, Leslie I, Northcote D, Bozhanova G, Crespo-Rodriguez E, Baldock H, Whittock H, Baker G, Kyula J, Guevara J, Melcher AA, Harper J, Ghadially H, Smith S, Pedersen M, McLaughlin M, Harrington KJ. Patin EC, et al. Among authors: melcher aa. J Immunother Cancer. 2022 Mar;10(3):e004306. doi: 10.1136/jitc-2021-004306. J Immunother Cancer. 2022. PMID: 35314434 Free PMC article.
93 results